Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

One shipment of suspected counterfeit Wegovy was hidden inside a Mickey Mouse puzzle for ... FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also ...

Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 drugs like Wegovy and Zepbound. To catch full episodes of all The Motley Fool's free podcasts, check out our ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

More patients come forward with stories about the pains they've suffered since beginning Ozempic, joining a growing number of ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The Mounjaro manufacturer, Eli Lilly, said patient safety was the company’s top priority ... Due to the soaring demand for ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Novo Nordisk’s Wegovy has so far not been approved in India, and while rival drugmaker Eli Lilly was green-lighted for its ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...